Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?

被引:124
作者
Zimetbaum, Peter J. [1 ]
Thosani, Amit
Yu, Hsing-Ting [2 ]
Xiong, Yan [2 ]
Lin, Jay [3 ]
Kothawala, Prajesh [2 ]
Emons, Matthew [2 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Cerner LifeSci, Beverly Hills, CA USA
[3] Sanofi Aventis, Bridgewater, NJ USA
关键词
Anticoagulation; Atrial fibrillation; Atrial flutter; Stroke risk; Warfarin; RHYTHM-CONTROL; ORAL ANTICOAGULATION; MANAGEMENT; THERAPY; PREVENTION; GUIDELINES; IMPACT;
D O I
10.1016/j.amjmed.2009.11.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical guidelines for the management of atrial fibrillation and atrial flutter provide recommendations for anticoagulation based on patients' overall risk of stroke. To determine the real-world compliance of physicians with these recommendations, we conducted a retrospective cohort study examining the utilization of warfarin in atrial fibrillation/flutter patients by stroke risk level. METHODS: Patients with a qualifying atrial fibrillation/flutter diagnosis during >= 18 months' continuous enrollment between January 2003 and September 2007, and with >= 6 months' eligibility after the first atrial fibrillation/flutter diagnosis, were identified from the US Market Scan database (Thomson Reuters, New York, NY). Warfarin use within 30 days of the first diagnosis was assessed according to stroke risk, estimated using the Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke (CHADS(2)) score. RESULTS: Of 171,393 patients included in the analysis, 20.0% had a CHADS(2) score of 0 (low risk), 61.6% a score of 1-2 (moderate risk), and 18.4% a score of 3-6 (high risk). Warfarin, recommended for high stroke-risk patients, was given to only 42.1% of those with a CHADS(2) score of 3-6. A similar percentage of patients with moderate (43.5%) or low stroke risk (40.1%) received warfarin. Only 29.6% of high-risk, 33.3% of moderate-risk, and 34.1% of low-risk patients who were started on warfarin received. uninterrupted therapy for 6 months following their initial prescription. CONCLUSIONS: These data suggest that guideline recommendations that anticoagulation should be provided in accordance with stroke risk in atrial fibrillation patients are not routinely followed in clinical practice. The causes and clinical implications of under-utilization of anticoagulation in atrial fibrillation patients with high stroke risk warrant further study. (c) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 446-453
引用
收藏
页码:446 / 453
页数:8
相关论文
共 50 条
  • [41] Patients with atrial fibrillation and low risk of stroke: do they really need anticoagulation?
    Trusz-Gluza, Maria
    Filipecki, Artur
    Urbanczyk-Swic, Dagmara
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2015, 125 (09): : 678 - 684
  • [42] Factors Correlated with Anticoagulation Choice in Primary Care Patients with Atrial Fibrillation and High Stroke Risk: Anticoagulation for NVAF in Primary Care
    Weng, Chien-Hsiang
    Kuo, Hsu-Ko
    Aho, Benjamin
    McGookin, Edward D.
    Chan, Philip A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, 39 (16) : 3234 - 3242
  • [43] Atrial fibrillation and stroke prevention: is warfarin still an option? Yes
    Spence, J. David
    JOURNAL OF NEURAL TRANSMISSION, 2013, 120 (10) : 1447 - 1451
  • [44] Reduced risk of death with warfarin - results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke
    Asberg, Signild
    Eriksson, Marie
    Henriksson, Karin M.
    Terent, Andreas
    INTERNATIONAL JOURNAL OF STROKE, 2013, 8 (08) : 689 - 695
  • [45] RIVAROXABAN IN PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION
    Simonyi Gabor
    Medvegy Mihaly
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2012, 65 (11-12): : 365 - 368
  • [46] Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation The Loire Valley Atrial Fibrillation Project
    Lip, Gregory Y. H.
    Clementy, Nicolas
    Pericart, Lauriane
    Banerjee, Amitava
    Fauchier, Laurent
    STROKE, 2015, 46 (01) : 143 - 150
  • [47] Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke
    Mitropoulou, Christina
    Fragoulakis, Vasilios
    Bozina, Nada
    Vozikis, Athanassios
    Supe, Svjetlana
    Bozina, Tamara
    Poljakovic, Zdravka
    van Schaik, Ron H.
    Patrinos, George P.
    PHARMACOGENOMICS, 2015, 16 (02) : 137 - 148
  • [48] Warfarin and Aspirin Use for Stroke Prevention Among Patients With Atrial Fibrillation: The US National Health and Wellness Survey
    Goren, Amir
    Liu, Xianchen
    Gupta, Shaloo
    Simon, Teresa A.
    Phatak, Hemant
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (04) : 248 - 256
  • [49] Asymptomatic atrial fibrillation and risk of stroke
    Stachon, P.
    Ahrens, I.
    Faber, T.
    Bode, C.
    Zirlik, A.
    PANMINERVA MEDICA, 2015, 57 (04) : 211 - 215
  • [50] Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation
    Waldo, Albert L.
    CARDIOLOGY CLINICS, 2009, 27 (01) : 125 - +